Latest Antivirals Stories
BARCELONA, April 19, 2012 /PRNewswire/ - Today Merck announced results demonstrating no difference in the rates of viral clearance between two anemia management strategies for patients with chronic hepatitis C virus (HVC) genotype 1 infection treated with VICTRELIS(TM) (boceprevir) in combination with peginterferon alfa-2b and ribavirin (P/R). Anemia is a common development of P/R therapy for chronic hepatitis C patients. For the patients studied, the anemia was either managed by...
BARCELONA, Spain, April 19, 2012 /PRNewswire/ -- Further data shows PegIFN-lambda's comparable efficacy but better safety profile than PegIFN-alpha New data presented at the International Liver Congress(TM) 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials[1],[2],[3],[4],[5],[6] confirm that combinations of antivirals offer the hope of...
BARCELONA, Spain, April 18, 2012 /PRNewswire/ -- - Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The data shows that similar...
WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress(TM) 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral...
BEERSE, Belgium, April 4, 2012 /PRNewswire/ -- Not Intended for US Journalists - Analysis to be presented at European Association for the Study of the Liver (EASL) 2012 shows clinical and cost-effectiveness regardless of IL28B subtype - Janssen Pharmaceutica NV (Janssen) will present a cost-effectiveness analysis for INCIVO(telaprevir) at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The analysis...
ABBOTT PARK Ill., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress(TM) 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Abstracts for the meeting were published online today. In the study known as "Co-Pilot," different doses of ABT-450/r,...
HUDDINGE, Sweden, April 4, 2012 /PRNewswire/ -- - Including an Oral Presentation of final analysis of the TMC435 phase IIb ASPIRE (C206) study that have been selected to be highlighted during the official EASL Press Office activities Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, today announces that four abstracts related to its once daily (QD), oral investigational hepatitis C drug TMC435, development in...
RESEARCH TRIANGLE PARK, N.C., April 3, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York City. Timothy W. Trost, Chief Financial Officer, will present at the Needham Healthcare Conference on Wednesday, April 4, 2012 at 10:40 am ET at the Palace Hotel. Kenneth I. Moch, President and Chief Executive Officer, will present at the Future Leaders in the...
HUDDINGE, Sweden, March 13, 2012 /PRNewswire/ -- - Study in previous non-responder Hepatitis C genotype-1 infected patients - Study in Hepatitis C genotype-4 infected patients MedivirAB (OMX: MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has...
A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy tissue. "Knowing the structure and properties of the transporter molecule may be the key to changing the way that some chemotherapies, for example, could work in the body to prevent tumor growth," said senior author Seok-Yong Lee, Ph.D., assistant professor of...
